Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Delcath Systems, Inc. (DCTH) Bolsters Global Marketing Team With Strategic Pharma Oncology Hire

|Includes: Delcath Systems, Inc. (DCTH)

Delcath Systems announced the appointment of Jennifer Simpson, Ph.D., M.S.N., C.R.N.P., to the position of Executive Vice President, Global Marketing. Ms. Simpson will use her extensive pharmaceutical and oncology marketing background to lead Delcath's global product marketing, brand management and reimbursement programs in the European Union, United States, and other key markets. In line with Ms. Simpson's appointment, Agustin Gago, Delcath's Executive Vice President for Global Sales & Marketing since 2009, will assume the new role of Executive Vice President, Global Sales. Ms. Simpson and Mr. Gago will both report to Eamonn P. Hobbs, President and CEO of Delcath. Both appointments were effective as of March 23, 2012.

Ms. Simpson has a wealth of experience in global product development in the oncology sector. Before bringing her talents and knowledge to Delcath, Ms. Simpson served as the Vice President, Global Marketing, Oncology Brand Lead at ImClone Systems, Inc. (a wholly-owned subsidiary of Eli Lilly and Company). As Vice President, she successfully handled all product commercialization activities and launch preparation for one of the late stage assets. During her time at ImClone, Ms. Simpson also excelled in various positions of increasing responsibility including Vice President, Product Champion and the Associate Vice President, Product Champion.

In addition to her successes at ImClone, Ms. Simpson held multiple leadership positions at Ortho Biotech (now Janssen Biotech), a Pennsylvania-based biotech company that focuses on innovative solutions in immunology, oncology, and nephrology. Before her stint at Ortho Biotech, Ms. Simpson acquired over 10 years of experience as an oncology-nurse practitioner and educator.

"The appointment of Jennifer Simpson adds significant oncology expertise and leadership to our marketing team," said Mr. Hobbs, President and CEO of Delcath. "Over the last year, we've made a concerted effort to build our talent base in order to drive the launch of our CHEMOSAT system. Jennifer's extensive experience in cancer treatment as a nurse, educator, marketer and strategic planner, combined with an intimate knowledge of the commercialization process makes her an ideal fit. We're confident that she will help us realize the full global market potential of CHEMOSAT."

"The planned transition of Mr. Gago to the position of Executive Vice President, Global Sales will allow him to fully devote his energies to the execution of our global commercial sales strategy. Through Mr. Gago's sales leadership, we are successfully implementing our launch plan for CHEMOSAT in the EU, and will continue to expand the opportunity for CHEMOSAT in new markets around the world."

Please see disclaimer on the QualityStocks website: